Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2004

View Archived Issues

Japanese approval for Hepsera

New indication for Sandostatin injection approved in Japan

FDA approval for Fosrenol

Guilford researchers present novel NAALADase inhibitors

Novel antibacterial methionyl tRNA synthetase inhibitors claimed by Replidyne

New antirotavirus agents prepared and tested at ViroPharma

Encysive scientists design new urotensin II antagonists

New GSK-3beta inhibitors and their use in Alzheimer's disease and other disorders

New alpha2delta-selective calcium channel ligands discovered at Pfizer

Gruenenthal describes new NOS inhibitors with analgesic activity

New fungal derivative with antitumor and antiproliferative properties

Enrollment progressing ahead of schedule in Ranexa angina study

CuraGen highlights pipeline progression

CuraGen and Bayer advance diabetes compound into preclinical development

Merck KGaA grants Lilly rights to 5-HT2A antagonist for insomnia

Serono and Paratek to develop oral disease-modifying treatment for MS

Approvable letter for Alvesco for persistent asthma

Allergan files IND for neuropathic pain compound

Cloretazine receives orphan drug status

Phase II study of IMOxine in renal cell carcinoma opens enrollment

GlaxoSmithKline acquires rights to Albugon

Lobeline enters clinical trials for methamphetamine addiction

Clearazide set to enter phase II/III studies in 2005

Novo Nordisk terminates development of balaglitazone

CY-401 active against VRSA in preclinical study

International Wex Technologies changes corporate name

Preclinical and clinical data support the efficacy of DA-8159 in erectile dysfunction

Torcetrapib increases plasma HDL cholesterol levels and prevents atherosclerosis in rabbits

Short-term efficacy of a combination of JTT-705 plus pravastatin in type II dyslipidemia

Rimonabant reported to improve insulin response in obese patients with dyslipidemia

Clinical phase I/II data on CAT-192 in diffuse systemic sclerosis

AMG-714 safe, active in rheumatoid arthritis

TNF-alpha antibody evaluated in rheumatoid arthritis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...